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Abstract: We welcome the comments regarding our article1 from Drs Mader and White, who have
published several articles on refractive changes induced by hypoxia in subjects after refractive surgery.
We value their additional account of the mechanism of the corneal changes in Dr Beck Weathers’ eyes
during his climb on Mount Everest that led to severe vision loss. This is an interesting amendment to
our manuscript, which focuses primarily on mountaineers with healthy corneas.
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tified in this clinical situation. Justification for a random-
ized clinical trial usually includes the following8: (1) evidence
of a significant public health problem, (2) a scientifically
plausible intervention, (3) preliminary information thatwar-
rants the trial, and (4) the ability to enroll a significant num-
ber of patients, with an outcome obtained within a reason-
able time frame. Regarding the criteria above, we believe a
randomized clinical trial is not justifiable because (1) while
intravitreal injections are common, endophthalmitis fol-
lowing injections may not be, (2) the intervention has not
previously been proven to be scientifically plausible, (3) there
is not sufficient preliminary information from endophthal-
mitis rates following this intervention or even other inter-
ventions such as those that occur during cataract surgery
(and risks of endophthalmitis following cataract surgery
would not be expected to be the same as risks following an
intravitreal injection of a drug using a 30 gauge needle),
and (4) enrollment for between 1.5 million and 15 million
injections, depending on outcome assumptions, could take
so many years that the antibiotic and intravitreal proce-
dure being tested may no longer be relevant.
We agree that it is important to determine the risk of en-
dophthalmitis after an intravitreal drug injection when topi-
cal antibiotics are not required either before, during, or af-
ter the injection because there is little scientific rationale to
support topical antibiotic use in this situation. As Drs Zi-
emssen andBartz-Schmidt state, omitting its usewould avoid
the cost, potential toxicity, and burden to patients follow-
ing millions of intravitreal injections each year. To address
this situation in the absence of randomized clinical trials,
which may not be justified, we hope to continue to provide
information that is of potential value related to the millions
of intravitreal injections currently provided around theworld
for common retinal conditions.
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Corneal Thickness Changes
in Very-High-Altitude Mountaineers
B osch and colleagues
1 performed a very nice study
of corneal thickness at high altitude. However,
some statements may benefit from clarification.
Specifically, “BesidesAMS [acutemountain sickness], cor-
neal changes during high-altitude climbs may also be a
dangerous hazard owing to a potential significant de-
crease in visual acuity. The often-quoted experience of
Dr BeckWeathers, aMount Everest climber who had un-
dergone radial keratotomy prior to ascent and incurred
severe vision loss during the climb, is such an ex-
ample.” The authors correctly imply that corneal thick-
ening plays a major role in radial keratotomy visual
changes at high altitude.However, themechanismof these
changes is a bit more complicated and warrants a more
precise explanation.
It is well known that any cornea thickens with expo-
sure to hypoxia.2,3 However, when the normal corneal
architecture is weakened by radial incisions, the hy-
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poxic cornea remains clear but the incisions may allow
swelling to occur in an anterior direction. This anterior
elevation in themidperiphery causes central corneal flat-
tening and a resultant hyperopic shift.2,3 Thus, alter-
ations in corneal structure caused by radial keratotomy
incisions, combinedwith increased corneal thickness, ac-
count for the induced refractive changes. Although plus
lenses were required for clear vision, a climber with bi-
lateral radial keratotomy successfully ascended Mount
Everest (8 850m).4 Similarly, owing to structural change
from flap creation, corneas that receive Lasik and are ex-
posed to hypoxia are thought to have a preferential cen-
tral expansion, causing a slight myopic shift.5 This con-
trasts with normal and photorefractive keratectomy
corneas that do not undergo refractive change with hy-
poxia because they thicken uniformly, thus preserving
the shape of the anterior corneal surface.
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We welcome the comments regarding our article1 from Drs
Mader and White, who have published several articles on
refractive changes induced by hypoxia in subjects after re-
fractive surgery. We value their additional account of the
mechanism of the corneal changes in Dr Beck Weathers’
eyes during his climb on Mount Everest that led to severe
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Correction
Error in Table. In the Clinical Sciences article titled
“Clinical Classification of Childhood Glaucomas” by
Yeung and Walton, published in the June issue of the
Archives (2010;128[6]:680-684), the Table was format-
ted incorrectly. In the right column, the subheading
“Trabecular Meshwork Endothelialization” should not
have been a subheading. It should be aligned below
“Iris bombe with pupillary block” under “Angle-block-
age mechanisms,” and there should have been no line
above it. The only two column subheadings should
have been “Primary (Developmental) Glaucomas” and
“Secondary (Acquired) Glaucomas.”
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